JP2022534962A5 - - Google Patents

Info

Publication number
JP2022534962A5
JP2022534962A5 JP2021570724A JP2021570724A JP2022534962A5 JP 2022534962 A5 JP2022534962 A5 JP 2022534962A5 JP 2021570724 A JP2021570724 A JP 2021570724A JP 2021570724 A JP2021570724 A JP 2021570724A JP 2022534962 A5 JP2022534962 A5 JP 2022534962A5
Authority
JP
Japan
Prior art keywords
cells
population
human
nucleic acid
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021570724A
Other languages
English (en)
Japanese (ja)
Other versions
JP7631234B2 (ja
JP2022534962A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/035579 external-priority patent/WO2020243713A2/en
Publication of JP2022534962A publication Critical patent/JP2022534962A/ja
Publication of JP2022534962A5 publication Critical patent/JP2022534962A5/ja
Application granted granted Critical
Publication of JP7631234B2 publication Critical patent/JP7631234B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021570724A 2019-05-31 2020-06-01 Ｃｄ３３陽性悪性腫瘍治療用ｃｄ３３標的化キメラ抗原受容体修飾ｔ細胞 Active JP7631234B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962855906P 2019-05-31 2019-05-31
US62/855,906 2019-05-31
PCT/US2020/035579 WO2020243713A2 (en) 2019-05-31 2020-06-01 Cd33 targeted chimeric antigen receptor modified t cells for treatment of cd33 positive malignancies

Publications (3)

Publication Number Publication Date
JP2022534962A JP2022534962A (ja) 2022-08-04
JP2022534962A5 true JP2022534962A5 (https=) 2023-06-09
JP7631234B2 JP7631234B2 (ja) 2025-02-18

Family

ID=71842756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021570724A Active JP7631234B2 (ja) 2019-05-31 2020-06-01 Ｃｄ３３陽性悪性腫瘍治療用ｃｄ３３標的化キメラ抗原受容体修飾ｔ細胞

Country Status (6)

Country Link
US (1) US12565658B2 (https=)
EP (1) EP3976794A2 (https=)
JP (1) JP7631234B2 (https=)
CN (1) CN114040978B (https=)
CA (1) CA3142159A1 (https=)
WO (1) WO2020243713A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202110873A (zh) 2019-04-30 2021-03-16 美商聖堤生物科技股份有限公司 嵌合受體及其使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106795221B (zh) 2014-04-03 2022-06-07 塞勒克提斯公司 用于癌症免疫治疗的cd33特异性嵌合抗原受体
CN105384823A (zh) * 2014-08-26 2016-03-09 中国人民解放军总医院 嵌合抗原受体及其基因和重组表达载体、工程化cd33靶向性的nkt细胞及其应用
CN104877032B (zh) * 2015-06-26 2018-12-11 中国医学科学院血液病医院（血液学研究所） Cd33特异性嵌合抗原受体及其应用
CA2992989A1 (en) 2015-07-21 2017-01-26 City Of Hope T cells for expression of chimeric antigen receptors and other receptors
MX389194B (es) * 2015-10-06 2025-03-20 Univ Minnesota Compuestos terapéuticos y métodos.
EP4613776A3 (en) 2016-10-21 2025-11-26 Altor BioScience Corporation Multimeric il-15-based molecules
CN110650975B (zh) * 2017-05-15 2024-04-05 美国卫生和人力服务部 双顺反子嵌合抗原受体及其用途
CN107353343A (zh) * 2017-07-04 2017-11-17 武汉波睿达生物科技有限公司 一种靶向表达cd33表面抗原的细胞的嵌合抗原受体
CN107267619A (zh) * 2017-07-04 2017-10-20 武汉波睿达生物科技有限公司 一种检测靶向cd33的cart细胞中car表达的荧光定量试剂盒
EA202092044A1 (ru) 2018-03-14 2021-03-03 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные рецепторы антигена против cd33 и их применения

Similar Documents

Publication Publication Date Title
Kong et al. Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm
CN102271702B (zh) 抗第三方中枢记忆性t细胞、产生其的方法及其在移植和疾病治疗中的用途
Vacchelli et al. Trial Watch: Adoptive cell transfer for anticancer immunotherapy
Colvin et al. Nonengraftment haploidentical cellular immunotherapy for refractory malignancies: tumor responses without chimerism
JP2018533625A5 (https=)
ES3036762T3 (en) A modulatable switch for selection of donor modified cells
ES2589678T3 (es) Uso de linfocitos T de memoria central anti-terceros para el tratamiento anti-leucemia/linfoma
Zhong et al. Immunotherapy for hepatocellular carcinoma: current limits and prospects
Wei et al. Effects of tumor irradiation on host T-regulatory cells and systemic immunity in the context of adoptive T-cell therapy in mice
Cheng et al. CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory/relapsed B-cell non-Hodgkin lymphoma
Chen et al. Hypofractionated irradiation suppressed the off-target mouse hepatocarcinoma growth by inhibiting myeloid-derived suppressor cell-mediated immune suppression
Tang et al. miR-aculous new avenues for cancer immunotherapy
Ciantra et al. The rewired immune microenvironment in leukemia
ES2869624T3 (es) Inmunoterapia para el tratamiento de cáncer
JP2022534962A5 (https=)
Grisendi et al. Tumor stroma manipulation by MSC
Chen et al. Nanomedicine strategies for ameliorating cancer by targeting immunosenescence: From challenge to opportunity
Cui et al. Decitabine for relapsed acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation
CA2942214C (en) Combination therapy with double negative t-cells
Locatelli et al. Strategies to optimize the outcome of children given T-cell depleted HLA-haploidentical hematopoietic stem cell transplantation
Kloss et al. 638. TGFBeta signaling blockade within PSMA targeted CAR human T cells for the eradication of metastatic prostate Cancer
Rook et al. Use of biological response modifiers in the treatment of cutaneous T-cell lymphoma
US12121554B2 (en) Materials and methods for treatment with oncolytic viruses and modified CAR T cells
Villa et al. Virotherapy as potential adjunct therapy for graft-vs-host disease
Gandhi et al. A comparison of CD34+ cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: a case controlled analysis